Inventor · disambiguated record
Karl Dane Wittrup
Also filed as: WITTRUP KARL DANE
29 granted patents·17 pending applications·202 citations·filing 1995–2025
95Inventor score
Files withMASSACHUSETTS INST TECHNOLOGY25ADIMAB LLC4Nodus Therapeutics3ANKYRA THERAPEUTICS INC2MEMORIAL SLOAN KETTERING CANCER CENTER2
Top patents by PatentIndex Score
46 records- 0196US8349311B2Mutant interleukin-2 (IL-2) polypeptidesMASSACHUSETTS INST TECHNOLOGY·Filed 2011·Granted Jan 8, 2013·40 cites·21 claims
- 0295US10350266B2Method of treating cancer with a multiple integrin binding Fc fusion proteinNodus Therapeutics·Filed 2017·Granted Jul 16, 2019·18 cites·17 claims
- 0394US9844582B2Synergistic tumor treatment with extended-PK IL-2 and therapeutic agentsMASSACHUSETTS INST TECHNOLOGY·Filed 2013·Granted Dec 19, 2017·38 cites·41 claims
- 0493US10166273B2Synergistic tumor treatment with antibodies targeting PD-1, PD-L1 or CTLA4 and integrin-binding-Fc-fusion proteinMASSACHUSETTS INST TECHNOLOGY·Filed 2015·Granted Jan 1, 2019·19 cites·20 claims
- 0591US11448643B2Methods to specifically profile protease activity at lymph nodesMASSACHUSETTS INST TECHNOLOGY·Filed 2017·Granted Sep 20, 2022·5 cites·16 claims
- 0690US11459389B2Monoclonal antibodies that bind human CD161MASSACHUSETTS INST TECHNOLOGY·Filed 2020·Granted Oct 4, 2022·3 cites·16 claims
- 0787US11096989B2Synergistic tumor treatment with an extended pharmacokinetic IL-2 and integrin-binding-Fc fusion proteinUNIV LELAND STANFORD JUNIOR·Filed 2018·Granted Aug 24, 2021·3 cites·31 claims
- 0885US10888603B2Methods of treating cancer cells expressing tumor-associated integrinsMASSACHUSETTS INST TECHNOLOGY·Filed 2017·Granted Jan 12, 2021·4 cites·35 claims
- 0985US10603358B2Combination tumor treatment with an integrin-binding-Fc fusion protein and immune stimulatorNodus Therapeutics·Filed 2018·Granted Mar 31, 2020·2 cites·19 claims
- 1084US11390964B2Polyclonal mixtures of antibodies, and methods of making and using themADIMAB LLC·Filed 2020·Granted Jul 19, 2022·1 cites·10 claims
- 1183US12383589B2Synthetic oncolytic LNP-replicon RNA and uses for cancer immunotherapyMASSACHUSETTS INST TECHNOLOGY·Filed 2023·Granted Aug 12, 2025·0 cites·19 claims
- 1283US10988534B2Multi-specific antibodies with affinity for human A33 antigen and DOTA metal complex and uses thereofMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2016·Granted Apr 27, 2021·2 cites·16 claims
- 1383US2023399386A1Rationally designed, synthetic antibody libraries and uses thereforADIMAB LLC·Filed 2023·Application pending·0 cites
- 1481US12433946B2Immunomodulatory fusion protein-metal hydroxide complexes and methods thereofMASSACHUSETTS INST TECHNOLOGY·Filed 2023·Granted Oct 7, 2025·0 cites·24 claims
- 1581US12258679B2Polyclonal mixtures of antibodies, and methods of making and using themADIMAB LLC·Filed 2022·Granted Mar 25, 2025·0 cites·16 claims
- 1681US11717548B2Synthetic oncolytic LNP-replicon RNA and uses for cancer immunotherapyMASSACHUSETTS INST TECHNOLOGY·Filed 2020·Granted Aug 8, 2023·1 cites·22 claims
- 1781US8648176B2Engineered proteins with high affinity for DOTA chelatesDAVIS ORCUTT KELLY·Filed 2010·Granted Feb 11, 2014·15 cites·40 claims
- 1876US10684289B2Polyclonal mixtures of antibodies, and methods of making and using themADIMAB LLC·Filed 2014·Granted Jun 16, 2020·1 cites·10 claims
- 1976US5773245AMethods for increasing secretion of overexpressed proteinsRES CORP TECHNOLOGIES INC·Filed 1995·Granted Jun 30, 1998·45 cites·13 claims
- 2073US8450247B2Cell display librariesPEELLE BEAU R·Filed 2005·Granted May 28, 2013·5 cites·31 claims
- 2172US2025327085A1Fusion polypeptidesANKYRA THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 2272US2023040528A1Methods to specifically profile protease activity at lymph nodesMASSACHUSETTS INST TECHNOLOGY·Filed 2022·Application pending·0 cites
- 2369US12454695B2Fusion polypeptides comprising interleukin 12 and a metal-hydroxide binding polypeptideANKYRA THERAPEUTICS INC·Filed 2022·Granted Oct 28, 2025·0 cites·20 claims
- 2469US11858993B2Multi-specific antibodies with affinity for human A33 antigen and DOTA metal complex and uses thereofMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2021·Granted Jan 2, 2024·0 cites·3 claims
- 2568US12227559B2Collagen-localized immunomodulatory molecules and methods thereofMASSACHUSETTS INST TECHNOLOGY·Filed 2022·Granted Feb 18, 2025·0 cites·10 claims
- 2668US11235032B2Combination immunotherapy dosing regimen for immune checkpoint blockadeMASSACHUSETTS INST TECHNOLOGY·Filed 2019·Granted Feb 1, 2022·0 cites·24 claims
- 2768US2022193197A1Synergistic tumor treatment with il-2 and integrin-binding-fc fusion proteinUNIV LELAND STANFORD JUNIOR·Filed 2021·Application pending·0 cites
- 2867US12295986B2Combination immunotherapy for treatment of melanoma, colon or non-small cell lung cancersMASSACHUSETTS INST TECHNOLOGY·Filed 2021·Granted May 13, 2025·0 cites·23 claims
- 2966US11642409B2Immunomodulatory fusion protein-metal hydroxide complexes and methods thereofMASSACHUSETTS INST TECHNOLOGY·Filed 2020·Granted May 9, 2023·0 cites·11 claims
- 3065US2025297240A1Bifunctional fusion proteins for ubiquitin-mediated degradationAXELYF EHF·Filed 2023·Application pending·0 cites
- 3158US2021077576A1Combination tumor treatment with an integrin-binding-fc fusion protein and immune stimulatorNodus Therapeutics·Filed 2020·Application pending·0 cites
- 3256US2023295284A1Enhanced-affinity anti-ecm nanobody-cytokine fusions and their applicationsMASSACHUSETTS INST TECHNOLOGY·Filed 2023·Application pending·0 cites
- 3353US2024156911A1Lung-cancer specific t cell dysfunctionMASSACHUSETTS INST TECHNOLOGY·Filed 2022·Application pending·0 cites
- 3451US2020102370A1Collagen-localized immunomodulatory molecules and methods thereofMASSACHUSETTS INST TECHNOLOGY·Filed 2019·Application pending·0 cites
- 3550US11485781B2Multiple specificity binders of CXC chemokinesMASSACHUSETTS INST TECHNOLOGY·Filed 2018·Granted Nov 1, 2022·0 cites·15 claims
- 3648US2015017120A1Synergistic tumor treatment with extended-pk il-2 and adoptive cell therapyMASSACHUSETTS INST TECHNOLOGY·Filed 2014·Application pending·0 cites
- 3747US12433954B2Methods of activating anti-CD19 chimeric antigen receptor (CAR) T cells using amphiphilic ligand conjugates comprising CAR-targeting protein sequence motifsMASSACHUSETTS INST TECHNOLOGY·Filed 2021·Granted Oct 7, 2025·0 cites·23 claims
- 3847US2017224777A1Synergistic tumor treatment with il-2, a therapeutic antibody, and a cancer vaccineMASSACHUSETTS INST TECHNOLOGY·Filed 2015·Application pending·0 cites
- 3947US2017216403A1Synergistic tumor treatment with il-2, a therapeutic antibody, and an immune checkpoint blockerMASSACHUSETTS INST TECHNOLOGY·Filed 2015·Application pending·0 cites
- 4046US2021340524A1Methods for identifying chimeric antigen receptor-targeting ligands and uses thereofMASSACHUSETTS INST TECHNOLOGY·Filed 2021·Application pending·0 cites
- 4144US11970542B2Bispecific antibodies specific for treating hematological malignanciesFRED HUTCHINSON CANCER CENTER·Filed 2018·Granted Apr 30, 2024·0 cites·7 claims
- 4242US2017252417A1Protein-chaperoned t-cell vaccinesMASSACHUSETTS INST TECHNOLOGY·Filed 2017·Application pending·0 cites
- 4341US2015174265A1Reversible masking of pore-forming proteins for macromolecular deliveryMASSACHUSETTS INST TECHNOLOGY·Filed 2013·Application pending·0 cites
- 4440US2014080766A1Compositions and methods for macromolecular drug deliveryPIRIE CHRISTOPHER MICHAEL·Filed 2012·Application pending·0 cites
- 4535US2012270797A1Engineered proteins including mutant fibronectin domainsWITTRUP KARL DANE·Filed 2010·Application pending·0 cites
- 4628US9464136B2Antibody-based constructs directed against tyrosine kinase receptorsWITTRUP KARL DANE·Filed 2011·Granted Oct 11, 2016·0 cites·9 claims
Join the waitlist — get patent alerts
Get an alert when Karl Dane Wittrup files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →